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Abstract: We aimed to investigate whether retinal and retinoic acid (RA), which are newly discovered
biomarkers from our previous research, reliably predict type 2 diabetes mellitus (T2DM) development
in subjects with impaired fasting glucose (IFG). Among the Korean Cancer Prevention Study (KCPS)-
II cohort, subjects were selected and matched by age and sex (IFG-IFG group, n = 100 vs. IFG-DM
group, n = 100) for study 1. For real-world validation of two biomarkers (study 2), other participants
in the KCPS-II cohort who had IFG at baseline (n = 500) were selected. Targeted LC/MS was used to
analyze the baseline serum samples; retinal and RA levels were quantified. In study 1, we revealed
that both biomarkers were significantly decreased in the IFG-DM group (retinal, p = 0.017; RA,
p < 0.001). The obese subjects in the IFG-DM group showed markedly lower retinal (p = 0.030) and
RA (p = 0.003) levels than those in the IFG-IFG group. In study 2, the results for the two metabolites
tended to be similar to those of study 1, but no significant difference was observed. Notably, the
predictive ability for T2DM was enhanced when the metabolites were added to conventional risk
factors for T2DM in both studies (study 1, AUC 0.682→ 0.775; study 2, AUC 0.734→ 0.786). The
results suggest that retinal- and RA-related metabolic pathways are altered before the onset of T2DM.
Keywords: type 2 diabetes mellitus; retinal; retinoic acid; biomarker; disease prediction; liquid
chromatography–mass spectrometry
1. Introduction
Type 2 diabetes mellitus (T2DM) is one of the most prevalent metabolic diseases
worldwide and induces many complications [1]. Thus, many studies have focused on
the alteration of metabolites prior to T2DM onset for the early prediction of T2DM risk
and prevention. Walford et al. [2] reported that metabolites, such as isoleucine, phenylala-
nine, tyrosine, triacylglycerides (TGs), phosphatidylcholines (PCs), and lysophosphatidyl-
cholines (lysoPCs), could be used as predictive biomarkers up to 13.4 years before the
onset of T2DM. The results of a nested case–control cohort study support the idea that
isoleucine, L-tyrosine, diacylglycerides (16:0/18:1), lysoPC (19:1), and PC (17:0/18:2) are
robustly predictive metabolites of T2DM [3]. Additionally, 2-hydroxyethanesulfonate and
PCs containing odd-chain acids (19:1 and 17:0) were identified as novel T2DM-predictive
markers in that study.
We previously found that vitamin A (VA)-related metabolites were associated with
the incidence of T2DM in impaired fasting glucose (IFG) females, further suggesting their
use as early predictive biomarkers of T2DM [4]. VA and its metabolites present in humans
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are derived from the bioconversion of carotenoids in food or preformed VA supplements.
Retinyl esters stored in the liver or adipose tissues are hydrolyzed into retinol when needed
and then bound to retinol-binding protein (RBP) to move to peripheral tissues [5]. The
enzymatic reaction converts retinol and beta-carotene to a biologically active form, namely,
retinoic acid (RA). RA controls the transcription of over 500 retinoid-responsive genes; thus,
it is linked with the regulation of adiposity, hepatic steatosis, glucose homeostasis, and
any other retinoid-responsive genes that are related to metabolism [6]. To date, the clinical
relevance of retinoid metabolism dysregulation related to T2DM is contradictory [7–9].
Here, we aimed to investigate whether retinal and RA reliably predict future T2DM de-
velopment, thereby providing clear insights into retinoid metabolism in T2DM progression.
To achieve our goal, we performed targeted metabolomics research via ultra-performance
liquid chromatography (UHPLC)-Q Exactive (QE) Orbitrap plus on two independent sets.
2. Results
2.1. Clinical and Biochemical Characteristics at Baseline
A summary of the overall baseline characteristics of all participants is presented in
Table 1. In study 1, 62 subjects were included in the IFG-IFG group and 55 subjects were
included in the IFG-DM group. The levels of glucose (p = 0.006), ALT (p = 0.020), and
GGT (p = 0.016) were significantly higher in the IFG-DM group than in the IFG-IFG group.
Each group was stratified by BMI (nonobese group vs. obese group) (Table 2). In the
nonobese subgroup (n = 58), the glucose level showed a significant difference between the
IFG-IFG group (n = 35) and the IFG-DM group (n = 23) (p = 0.020). On the other hand,
in the obese subgroup (n = 59), GGT showed a considerable difference between the two
groups (p = 0.017) (Table 2). No significant difference was observed in the other indicators.
Table 1. Baseline clinical and biochemical characteristics of the IFG-IFG and IFG-DM groups in the total population.
Study 1 Study 2
Total (n = 117)
p
Total (n = 500)
p
IFG-IFG (n = 62) IFG-DM (n = 55) IFG-IFG (n = 384) IFG-DM (n = 116)
Age (year) 48.2 ±1.41 49.3 ±1.23 0.564 48.1 ±0.53 52.9 ±0.91 <0.001
Male/female, n (%) 29 (46.8)/33 (53.2) 26 (47.3)/29 (52.7) 0.957 196 (51.0)/188 (49.0) 54 (46.6)/62 (53.5) 0.458
BMI (kg/m2) 25.3 ±0.43 26.1 ±0.43 0.197 24.8 ±0.16 26.1 ±0.30 <0.001
Waist circumference (cm) 84.4 ±1.17 86.4 ±1.01 0.188 83.3 ±0.45 87.1 ±0.85 <0.001
Systolic blood pressure (mmHg) 124.8 ±1.38 124.4 ±1.82 0.852 127.6 ±0.79 129.1 ±1.42 0.347
Diastolic blood pressure (mmHg) 78.2 ±1.20 77.8 ±0.87 0.757 79.3 ±0.63 77.1 ±1.13 0.105
Glucose (mg/dL) 109.0 ±0.89 113.0 ±1.13 0.006
∮
107.0 ±0.39 112.8 ±0.62 <0.001
Triglyceride (mg/dL) 140.6 ±9.95 149.9 ±10.5 0.465
∮
149.3 ±5.39 181.2 ±11.1 0.006
Total cholesterol (mg/dL) 191.9 ±3.85 191.7 ±4.34 0.897
∮
194.2 ±1.76 201.9 ±3.37 0.037
HDL-cholesterol (mg/dL) 50.2 ±1.08 50.6 ±1.32 0.932
∮
52.4 ±0.62 50.2 ±1.16 0.094
LDL-cholesterol (mg/dL) 117.7 ±3.33 112.1 ±4.05 0.202
∮
118.2 ±1.64 122.3 ±3.14 0.235
AST (IU/L) 22.9 ±1.29 23.9 ±1.02 0.204
∮
23.1 ±0.49 28.1 ±1.40 <0.001
∮
ALT (IU/L) 25.2 ±2.02 28.8 ±1.63 0.020
∮
25.8 ±0.97 37.7 ±3.57 <0.001 †
GGT (IU/L) 30.0 ±2.34 36.6 ±2.54 0.016
∮
39.1 ±1.99 47.4 ±4.94 0.008 †
Mean ± standard error (SE). Comparisons were conducted between the IFG-IFG group (IFG at baseline and follow-up) and the IFG-DM
group (IFG at baseline but developed DM after the 7-year mean follow-up period). Continuous variables were tested using an independent
t-test, and variables marked with
∮
were tested using a logarithmic transformation. Continuous variables with a nonnormal distribution,
even after the logarithmic transformation, were tested using a Mann–Whitney U test, and p-values are marked with †. Sex distribution
was tested using a chi-squared test. DM: diabetes mellitus, IFG: impaired fasting glucose, ALT: alanine aminotransferase, AST: aspartate
aminotransferase, BMI: body mass index, GGT: γ-glutamyltransferase, HDL: high-density lipoprotein, LDL: low-density lipoprotein.
In study 2384 subjects were included in the IFG-IFG group, and 116 subjects were
included in the IFG-DM group (Table 1). In the between-group comparison, age (p < 0.001),
BMI (p < 0.001), waist circumference (p < 0.001), glucose (p < 0.001), TG (p = 0.006), total
cholesterol (p = 0.037), AST (p < 0.001), ALT (p < 0.001), and GGT (p = 0.008) were signifi-
cantly higher in the IFG-DM group than in the IFG-IFG group. After BMI stratification, age
(p < 0.001), glucose (p < 0.001), and TG (p = 0.035) showed a significant difference between
the IFG-IFG group (n = 218) and the IFG-DM group (n = 45) in the nonobese subgroup
(n = 263). The obese subgroup (n = 237) showed a significant difference in age (p = 0.017),
BMI (p = 0.028), waist circumference (p = 0.015), glucose (p < 0.001), AST (p < 0.001), and
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ALT (p < 0.001) between the IFG-IFG group (n = 166) and the IFG-DM group (n = 71)
(Table 2).
Table 2. Baseline clinical and biochemical characteristics of the IFG-IFG and IFG-DM groups after stratification by BMI.
Study 1
Nonobese (n = 58) Obese (n = 59)
IFG-IFG (n = 35) IFG-DM (n = 23) p IFG-IFG (n = 27) IFG-DM (n = 32) p
Age (year) 47.1 ±2.10 50.5 ±1.95 0.268 49.6 ±1.75 48.4 ±1.59 0.921 †
Male/female, n (%) 20 (57.1)/15 (42.9) 13 (56.5)/10 (43.5) 0.963 9 (33.3)/18 (66.7) 13 (40.6)/19 (59.4) 0.564
BMI (kg/m2) 23.1 ±0.21 23.4 ±0.26 0.328 † 28.1 ±0.61 28.0 ±0.47 0.563 †
Waist circumference (cm) 80.7 ±1.08 80.7 ±1.22 0.974 89.2 ±1.92 90.3 ±0.92 0.607
Systolic blood pressure (mmHg) 125.3 ±2.06 125.5 ±2.77 0.951 124.2 ±1.75 123.6 ±2.44 0.850
Diastolic blood pressure (mmHg) 79.3 ±1.83 77.1 ±1.52 0.404 76.9 ±1.41 48.3 ±1.04 0.429 †
Glucose (mg/dL) 107.3 ±1.08 112.1 ±1.80 0.020
∮
111.0 ±1.41 113.6 ±1.47 0.219
Triglyceride (mg/dL) 129.7 ±10.8 137.8 ±16.5 0.859
∮
154.9 ±18.0 158.6 ±13.7 0.586
∮
Total cholesterol (mg/dL) 189.9 ±4.59 187.3 ±8.13 0.762 194.5 ±6.61 194.8 ±4.68 0.837 †
HDL-cholesterol (mg/dL) 51.5 ±1.26 51.2 ±2.20 0.903 48.6 ±1.84 50.3 ±1.66 0.501
LDL-cholesterol (mg/dL) 116.2 ±3.94 108.6 ±6.64 0.302 119.7 ±5.76 114.6 ±5.12 0.461 †
AST (IU/L) 21.3 ±1.31 21.7 ±1.39 0.799 † 24.9 ±2.39 25.5 ±1.40 0.156 †
ALT (IU/L) 23.5 ±2.58 24.9 ±2.14 0.106 † 27.4 ±3.22 31.6 ±2.23 0.081
∮
GGT (U/L) 29.1 ±3.29 28.2 ±2.30 0.553
∮
31.1 ±3.31 42.7 ±3.71 0.017
∮
Study 2
Nonobese (n = 263) Obese (n = 237)
IFG-IFG (n = 218) IFG-DM (n = 45) p IFG-IFG (n = 166) IFG-DM (n = 71) p
Age (year) 47.7 ±0.72 54.0 ±1.50 <0.001 48.8 ±0.80 52.2 ±1.15 0.017
Male/female, n (%) 100 (45.9)/118 (54.1) 17 (37.8)/28 (62.2) 0.407 96 (57.8)/70 (42.2) 37 (52.1)/34 (47.9) 0.416
BMI (kg/m2) 22.7 ±0.12 22.9 ±0.22 0.689 27.5 ±0.17 28.2 ±0.24 0.028
Waist circumference (cm) 78.5 ±0.50 79.2 ±1.05 0.555 89.6 ±0.54 92.0 ±0.78 0.015
Systolic blood pressure (mmHg) 124.7 ±1.06 124.3 ±2.27 0.877 131.4 ±1.11 132.1 ±1.75 0.728
Diastolic blood pressure (mmHg) 78.5 ±0.84 77.3 ±1.89 0.540 80.2 ±0.94 77.1 ±1.42 0.065
Glucose (mg/dL) 106.3 ±0.53 112.4 ±0.99 <0.001 107.9 ±0.57 113.0 ±0.79 <0.001
Triglyceride (mg/dL) 130.2 ±5.08 157.0 ±13.2 0.035 174.5 ±10.2 196.5 ±15.9 0.244
Total cholesterol (mg/dL) 192.5 ±2.37 198.6 ±4.80 0.281 196.5 ±2.62 204.1 ±4.59 0.133
HDL-cholesterol (mg/dL) 54.4 ±0.88 52.3 ±1.93 0.331 49.8 ±0.81 48.9 ±1.44 0.563
LDL-cholesterol (mg/dL) 118.2 ±2.07 120.3 ±4.81 0.666 118.3 ±2.65 123.6 ±4.14 0.280
AST (IU/L) 21.8 ±0.62 23.5 ±1.34 0.269 24.7 ±0.76 31.1 ±2.05 <0.001 †
ALT (IU/L) 22.9 ±1.17 24.7 ±2.40 0.539 29.5 ±1.60 45.9 ±5.43 <0.001
∮
GGT (U/L) 32.6 ±2.36 43.9 ±11.01 0.126
∮
47.6 ±3.28 49.6 ±4.13 0.731
Mean ± standard error (SE). Comparisons were conducted between the IFG-IFG group (IFG at baseline and follow-up) and the IFG-
DM group (IFG at baseline but developed DM after the 7-year mean follow-up period) in each stratified subset (nonobese and obese).
Continuous variables with a normal distribution were tested using an independent t-test; the variables with p-values marked with
∮
were
tested following a logarithmic transformation to fit a normal distribution. Continuous variables with a nonnormal distribution, even after
logarithmic transformation, were tested using a Mann–Whitney U test, and p-values are marked with †. Sex distribution was tested using a
chi-squared test. DM: diabetes mellitus, IFG: impaired fasting glucose, ALT: alanine aminotransferase, AST: aspartate aminotransferase,
BMI: body mass index, GGT: γ-glutamyltransferase, HDL: high-density lipoprotein, LDL: low-density lipoprotein.
2.2. Method Validation of UHPLC-QE Orbitrap Plus MS Analysis
The results of our UHPLC-QE Orbitrap plus MS method validation are shown in
Table 3. As shown in Table 3, the calibration curves of both metabolites of interest were
well fitted linearly. With regard to limit of detection (LOD) and limit of quantitation (LOQ),
the amounts of RA detected using UHPLC-QE Orbitrap plus MS were below the LOQ
in the majority of the samples. Therefore, the quantity of RA was calculated (relative
quantification) for the statistical analysis of the data; the RA peak area was divided by the
IS peak area.
2.3. Serum Retinal and Retinoic Acid Analysis Using UHPLC-QE Orbitrap Plus MS
In study 1, the levels of retinal (p = 0.017) and RA (p < 0.001) were significantly lower
in the IFG-DM group than in the IFG-IFG group (Figure 1). Similar trends were also
observed in the obese subgroup; retinal and RA were significantly lower in the IFG-DM
group (p = 0.030 and p = 0.003, respectively) (Figure 2). In the nonobese subgroup, only RA
(p = 0.023) was markedly lower in the IFG-DM group. On the other hand, no significant
difference was confirmed in study 2.
Metabolites 2021, 11, 510 4 of 12
Table 3. Results of method validation.
Retinal Retinoic Acid
R2 of calibration curves (linearity) 0.9956 0.9959
LOQ (ng/mL) 1.63 24.5
Precision assessments
Intra-assay variation (%RSD) 0.0268 0.0497
Inter-assay variation (%RSD) 0.0304 0.0645
Accuracy assessments
Recovery (%) SD (%) Recovery (%) SD (%)
Recovery at low concentration 93.5 3.83 48.2 6.50
Recovery at high concentration 90.8 7.63 93.1 3.93
For the accuracy assessments, recovery was calculated at two different (low and high) concentrations. For the low
concentration, 1 ng/mL and 20 ng/mL retinal and retinoic acid stock solutions were used, respectively, and for
the high concentration, 5 ng/mL and 40 ng/mL retinal and retinoic acid stock solutions were used. One hundred
microliters of spare serum samples was spiked with 25 µL of each stock solution at different concentrations and
then analyzed three times. LOQ: limit of quantification, RSD: relative standard deviation.
Figure 1. Results of the targeted UHPLC/MS analysis of retinal and retinoic acids between the IFG-
IFG and IFG-DM groups. Mean± standard error (SE). § tested following a logarithmic transformation.
p-values were derived from an independent t-test; comparison of the baseline levels of retinal and
retinoic acids between the IFG-IFG group (IFG at baseline and follow-up) and the IFG-DM group
(IFG at baseline but DM developed after the 7-year mean follow-up period). * p < 0.05, ** p < 0.01, and
*** p < 0.001 were the results of the within-group comparisons of each group. DM: diabetes mellitus,
IFG: impaired fasting glucose, ISTD: internal standard, RA: retinoic acid.
2.4. Logistic Regression Analysis
Logistic regression analysis was performed to evaluate the independent prediction
ability of retinal and RA for T2DM. We constructed each logistic regression model using a
combination of conventional risk factors, retinal, and RA (Figure 3). In study 1, an area
under the curve (AUC) of 0.682, consisting of traditional risk factors (glucose, ALT, GGT),
was significantly improved by adding retinal and RA, with an AUC of 0.775. The predictive
ability of the model with retinal and RA (AUC = 0.786) was also stronger than that of a
conventional model consisting of glucose, ALT, and GGT (AUC = 0.734) in study 2.
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Figure 2. Results of the targeted UHPLC/MS analysis on retinal and retinoic acids between the
IFG-IFG and IFG-DM groups stratified by BMI. Mean ± standard error (SE). § tested following a
logarithmic transformation. p-values were derived from an independent t-test; comparison of the
baseline levels of retinal and retinoic acids between the IFG-IFG group (IFG at baseline and follow-up)
and the IFG-DM group (IFG at baseline but DM developed after the 7-year mean follow-up period).
* p < 0.05, ** p < 0.01, and *** p < 0.001 were the results of the within-group comparisons of each group.
DM: diabetes mellitus, IFG: impaired fasting glucose, ISTD: internal standard, RA: retinoic acid.
Figure 3. ROC curves for the prediction of T2DM. (a) Prediction models with all subjects in study
1 (n = 117). The blue line is a prediction model consisting of conventional risk factors (glucose,
ALT, GGT) for DM. The pink line is a new prediction model with the metabolites associated with
DM development (glucose, ALT, GGT, retinal, retinoic acid). The gray line is a reference line.
(b) Prediction models with all subjects in study 1 (n = 500). The blue line is a prediction model
consisting of conventional risk factors (glucose, ALT, GGT) for DM. The red line is prediction model
3 consisting of risk factors (age, BMI, waist circumference, glucose, ALT, GGT, retinal, retinoic acid)
for DM. The gray line is a reference line.
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3. Discussion
This cohort study confirmed that retinal and RA are valuable biomarkers for predicting
T2DM risk in Korean subjects with IFG. In study 1, both retinal and RA were significantly
lower in the IFG-DM group than in the IFG-IFG group. From this result, we could infer
that subjects with abnormal retinoid metabolism were at high risk of developing T2DM.
Although a significant difference in retinal and RA levels between the two groups could
not be confirmed in study 2, the predictive power for T2DM was further improved in the
prediction model in both studies when adding retinal and RA to the conventional risk
factors. Notably, retinal showed significance in the T2DM prediction, even in the real-world
validation (study 2).
Our findings are in line with some previous studies. Yan Liu et al. [7,8] showed
that the concentration of serum RA determined by enzyme-linked immunosorbent assay
(ELISA) was significantly lower in T2DM subjects than in normal glucose tolerance subjects;
furthermore, it was inversely associated with ALT, AST, GGT, total cholesterol (TC), and
TG, which are traditionally considered T2DM risk factors. Cardiovascular and renal
disease, which are well-known complications of DM, also have a deep association with
RA. Subjects with coronary artery disease whose circulating RA level was low had a
high mortality risk [10]. Agrawal et al. [11] reported that retinoic acid response element
(RAR)-α plays a crucial role in renal protection by repairing endogenous RA synthesis.
In addition, several epidemiological studies have also revealed that serum carotenoids
are negatively correlated with the development of metabolic syndrome. Among Japanese
subjects who participated in the longitudinal cohort, people who consumed carotenoids
had lower metabolic syndrome incidence and maintained appropriate glucose control
ability than people whose carotenoid intake was lower [12]. Similar results were shown
for middle-aged and elderly Chinese adults [13]. However, some clinical studies have
reported higher serum VA levels in T2DM patients than in nondiabetic controls [9,14].
Additionally, the differences in serum VA levels seen between types of diabetes have not
yet been thoroughly explained.
The mechanisms that could explain the lower retinoid levels in the IFG-DM group
shown in our study are as follows. The secretion of nonesterified fatty acids (NEFAs) and
proinflammatory cytokines increases when body fat increases [15]. Elevated NEFA levels
are a hallmark of obesity and T2DM [16,17]. Intracellular NEFAs reduce pyruvate dehydro-
genase, phosphofructokinase, and hexokinase II activities while competing with glucose
for energy production [18]. Furthermore, increased NEFA levels induce intracellular fatty
acid induction, which induces phosphorylation of serine/threonine sites on the insulin
receptor, disrupting downstream insulin receptor signaling [19]. Our findings supported
these phenomena; although obese subjects in study 1 showed no significant difference in
glucose levels between the two groups, the levels of retinal and RA were significantly lower
in the IFG-DM group. In other words, retinoid levels may change before a substantial
change in glucose occurs. This suggests that retinal and RA can be utilized as essential
biomarkers that are comparable to glucose, which is widely used for diabetes diagnosis.
The lower retinoid concentrations shown in the IFG-DM group may indicate abnormal
blood glucose control that is closely related to fat accumulation. Some evidence has
supported the idea that the action of RA as a ligand of the RAR and retinoid X receptor
(RXR) can appropriately control glucose and lipid metabolism [20]. Starkey et al. observed
that all-trans-RA levels were decreased, accompanied by reduced peroxisome proliferator-
activated receptor (PPAR)-β/δ mRNA levels in diabetic mouse kidney tissue [21]. The
RAR/RXR dimer binds to the retinoic acid response element (RARE) of target genes, such
as glucokinase and SREBP-1c, in the presence of the ligand [22,23]. Glucokinase (Gck)
promotes glycogen synthesis and glycolysis [24], and Srebp-1c tends to store lipids rather
than utilize them, inducing lipogenesis and cholesterol esterification [25]. It is crucial
that retinoids stimulate Srebp-1c and Gck expression by synergizing with insulin. INS-1
cells treated with RA exhibited increased RARE-mediated Srebp-1c expression in a dose-
dependent manner [26]. Reduced expression of Gck mRNA in VA-deficient diet-fed rats
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was recovered with an intraperitoneal injection of RA [27]. Additionally, in rats fed a VA-
sufficient diet, an intravenous injection of RA increased hepatic glucokinase expression [28].
Although human studies exploring this mechanism are limited, retinoids and insulin seem
to play essential, synergistic roles in glucose and lipid metabolism.
Another possible mechanism is to consider the direct effect of retinoid metabolism
on pancreatic β-cells. Although reports still debate the concentration of serum retinoids
in T2DM and the link between the two factors, the concentration of retinoids is relatively
low in T1DM subjects [14]. From this point of view, the link between insulin secretion and
serum retinoids seems to be precise. Pancreatic β-cells, which produce insulin, become
dysfunctional and dedifferentiate during diabetes progression [28]. RA signaling during
endocrine specification appears to play a critical role in directing pancreatic endocrine cell
fate and function [29,30]. Mice fed a VA-deficient diet for eight weeks had reduced β-cell
mass, glucose-stimulated insulin secretion, and tissue VA levels [31]. Interestingly, VA-
deficient rats treated with VA replication or RA recovered glucose-induced insulin secretion
in perifused islets [32]. These results suggest the crucial role of retinoid metabolism in
normal glucose metabolism. At this point, we can infer the close relationship between
abnormal diabetes metabolism and the decreased retinoid concentrations observed in
IFG-DM subjects. We suggest that retinoids directly affect pancreatic β-cells, indirectly
regulating insulin secretion and action.
In addition, the control of glucose metabolism associated with retinoids suggested
in our study may be the basis for finding targets for T2DM prevention, management, and
treatment. RA has been considered a potential therapeutic agent for metabolic diseases
based on studies [33]. However, to date, no trials have directly explored the possible
treatment effect of RA on T2DM. The representative drugs that can be considered in
relation to the function of RA are pharmacological agonists of PPAR and RAR. PPAR-α
and RAR-β2 agonists improve dyslipidemia in insulin target tissues, and PPAR-γ agonists,
such as thiazolidinediones, improve insulin resistance [34,35]. Therefore, the facts revealed
in our study could be key concepts for research on T2DM, including T2DM development.
Our study has several limitations. First, the recovery rate of RA is lower in our
metabolomics platform; therefore, further research on RA needs to be performed with the
developed analysis methods. Second, there was no information on carotenoid intake in our
cohort; it is difficult to draw conclusions about the correlations between carotenoid intake,
serum carotenoid, and T2DM occurrence. Despite these limitations, the same direction of
the main results shown on two independent sets with large sample sizes is noteworthy.
In conclusion, we confirmed the possibility that retinoids, especially retinal, can be used
as biomarkers along with glucose for predicting future T2DM risk in Korean subjects
with IFG.
4. Materials and Methods
4.1. Study Subjects
We used two independent sets (studies 1 and 2) to validate the two biomarkers.
Study subjects were recruited from the Korean Cancer Prevention Study (KCPS)-II cohort
(n = 156,701). Detailed characteristics of the KCPS-II cohort were described in our previous
study [4,36]. Briefly, the KCPS-II cohort comprises subjects who underwent a routine
check-up at 18 health promotion centers in Seoul and Gyeonggi Province, the Republic of
Korea, from 2004 to 2013 [37].
Among all KCPS-II subjects, age- and sex-matched subjects were randomly selected at a
ratio of 1:1 for 100 individuals with IFG (100 ≤ serum fasting glucose (mg/dL) < 126) at both
baseline and follow-up (IFG-IFG group) and 100 individuals who had IFG at baseline but
developed DM (serum fasting glucose ≥ 126 mg/dL) after a 7-year mean follow-up period
(IFG-DM group) for study 1. To investigate the predictive capacity of retinal and RA for
T2DM, individuals without any clinical or biochemical data for the statistical analysis and
who met the exclusion criteria were excluded (Figure 4). As a result, 62 and 55 individuals
were included in the IFG-IFG and IFG-DM groups, respectively.
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Figure 4. Analysis flow chart. IFG-IFG group: IFG at baseline and follow-up, IFG-DM group: IFG
at baseline but DM developed after the 7-year mean follow-up period, DM: diabetes mellitus, IFG:
impaired fasting glucose, KCPS: Korean Cancer Prevention Study.
For real-world validation of the two biomarkers (study 2), other participants in the
KCPS-II cohort who had IFG at baseline (n = 500) were selected without any exclusion
criteria. After all the experiments were completed, whether the subjects developed DM
was revealed to the researchers. After the exclusion of subjects without any clinical or bio-
chemical data for the statistical analysis, 102 people developed T2DM, and 367 maintained
IFG status during the 7-year mean follow-up period (Figure 4).
The Institutional Review Board of Yonsei University Health System reviewed and
approved the study, which complied with the Declaration of Helsinki principles (4-2014-
1008). We obtained written informed consent for a long-term prospective follow-up from
all participants.
4.2. Sample Collection and Clinical and Biochemical Assessments
We collected blood samples only at baseline to verify any differences regarding clinical
and biochemical assessments between the IFG-IFG and IFG-DM groups before T2DM
development. Peripheral venous blood specimens were taken from each subject after a
minimum 12 h fasting period. Serum was separated from the specimens via centrifugation,
and then, the serum aliquots were stored at −70 ◦C until further analysis.
To calculate the body mass index (BMI, kg/m2), the subjects’ height (cm) and body
weight (kg) were measured while they were wearing light clothing. Waist circumfer-
ence (cm) was measured midway between the lower rib and the iliac crest. Systolic and
diastolic blood pressures (mmHg) were measured while the subjects were sitting on a
chair after a specified rest period; most health check-up centers used standard mercury
sphygmomanometers, but automatic sphygmomanometers were also used at some of the
health check-up centers. Levels of fasting glucose, TG, TC, high-density lipoprotein (HDL)
cholesterol, low-density lipoprotein (LDL) cholesterol, white blood cell count, aspartate
transferase (AST), alanine aminotransferase (ALT), and γ-glutamyl transferase (GGT) were
measured using COBAS INTEGRA 800 (Hitachi, Tokyo, Japan) and 7600 (Hitachi, Tokyo,
Japan) analyzers. Each laboratory measurement was performed following internal and
external quality control procedures specified by the Korean Association of Laboratory
Quality Control. The agreement for each biomarker across individual hospitals was high
(correlation coefficients ranging from 0.96 to 0.99) [36].
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4.3. Targeted Metabolic Profiling with UHPLC-QE Orbitrap Plus MS Using Serum Samples
4.3.1. Preparation of Blood Samples
All preparation steps were performed in a dark room to protect the samples from light.
One hundred microliters of each serum sample was placed in a 1.5 mL microcentrifuge tube.
To precipitate proteins from serum, 275 µL of UPLC-grade acetonitrile (Wako Pure Chemical
Industries, Ltd., Osaka, Japan) was added to each sample and then centrifuged (15,000 rpm,
15 min, 4 ◦C). The supernatant was transferred into a new 1.5 mL microcentrifuge tube and
evaporated with nitrogen (N2) gas. The dried residue was dissolved in 50% UPLC-grade
methanol (J.T. Baker® Chemicals; Avantor Performance Materials, Inc., Randor, PA, USA)
for UHPLC-QE Orbitrap analysis. Retinal-d6 (Cambridge Isotope Laboratories, Andover,
MA, USA) diluted in UPLC-grade ethanol (J.T. Baker® Chemicals; Avantor Performance
Materials, Inc., Randor, PA, USA) was used as the internal standard (ISTD). Quality control
(QC) samples to be used as a reference to monitor the data quality of a multibatch set were
prepared by pooling all samples.
4.3.2. Preparation of Stock Solutions and Standard Samples
To generate calibration curves, stock solutions of the metabolites of interest (retinal
and RA) were produced at various concentrations (2.5, 5, 10, 20, 40, and 80 ng/mL), and
standard samples were prepared using stock solutions. To make stock solutions, powdered
retinal (Sigma-Aldrich, St. Louis, MO, USA) and RA (Sigma-Aldrich, St. Louis, MO, USA)
were diluted with UPLC-grade ethanol (J.T. Baker® Chemicals; Avantor Performance Mate-
rials, Inc., Randor, PA, USA) and n-hexane (J.T. Baker® Chemicals; Avantor Performance
Materials, Inc., Randor, PA, USA), respectively, according to the desired concentrations.
Using 100 µL of each stock solution, the standard samples were prepared by following the
same protocol used for serum sample preparation described above.
4.3.3. UHPLC-QE Orbitrap Plus MS Analysis
Ten microliters of each prepared serum sample and the standard sample were injected
into an Acquity UPLC-BEH-C18 column (2.1 × 50 mm, 1.7 µm; Waters, Milford, MA, USA)
equipped with a Thermo UHPLC system (Ultimate 3000 BioRS; Dionex-Thermo Fisher
Scientific, Bremen, Germany). The column temperature was maintained at 50 ◦C. Mobile
phases A (0.1% formic acid in LC/MS grade water; Thermo Fisher Scientific, Fair Lawn, NJ,
USA) and B (0.1% formic acid in LC/MS grade methanol; Thermo Fisher Scientific, Fair
Lawn, NJ, USA) were used with a volumetric concentration change in the range of 0–100%
for 22.0 min at 0.4 mL/min.
MS analysis was performed with an electrospray ionization (ESI) source using the QE
Orbitrap Plus (Thermo Fisher Scientific, Waltham, MA, USA). The MS conditions were
set as follows: spray voltage, 3.5 kV; flow rate of the N2 sheath gas, 40 arbitrary units;
flow rate of the auxiliary gas, 10 arbitrary units; capillary temperature, 320 ◦C; S-lens
radio frequency level, 50; tube lens voltage, 80 V; and auxiliary gas heater temperature,
300 ◦C. The MS data were acquired in a parallel reaction monitoring (PRM) assay, which is
a technique used for targeted quantification. When the standard samples were analyzed
with the PRM method, the conditions of precursor-to-product ion transition m/z were as
follows: retinal-d6: 291.2→ 167.1, retinal: 285.2→ 161.0, and RA: 301.2→ 283.1. Using the
conditions as a filter for selecting MS data obtained from the blood samples, metabolite
specificity was enhanced and background noise was reduced.
4.3.4. UHPLC-QE Orbitrap Plus MS Method Validation
A calibration curve with five concentration points (2.5, 5, 10, 20, 40, and 80 ng/mL)
was generated for each metabolite of interest; the metabolites of interest were measured
three times at every concentration. The LOD and LOQ of the metabolites of interest were
determined using the following equations: LOD = 3SD/SC and LOQ = 10SD/SC, where
SD is the standard deviation of the measurements of the metabolites of interest at each
concentration, and SC is the slope of the calibration curve.
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Precision was assessed by comparing data measured repeatedly from QC samples.
The intra-assay variation was estimated by analyzing six replicates of QC samples, and
the inter-assay variation was calculated by analyzing the QC samples on three different
days. The precision of the intra- and inter-assay is expressed as the relative standard
deviation (%RSD).
For accuracy assessments, 100 µL of spare serum samples was spiked with 25 µL of
each stock solution of the metabolites of interest, and then, recovery of the metabolites of
interest was calculated using the following equation: recovery (%) = [(A − B)/C] × 100,
where A is the amount of the metabolite of interest in 125 µL of the spiked sample, B is the
amount of the metabolite of interest in 100 µL of the serum sample, and C is the amount of
the metabolite of interest in 25 µL of the stock solution.
5. Statistical Analysis
Statistical analysis was conducted using SPSS version 25.0 (IBM/SPSS, Chicago, IL,
USA) and SAS 9.4 (SAS Institute Inc., Cary, NC, USA). We performed an independent t-test
to compare continuous variables between the two groups. Logarithmic transformations
were used for skewed variables, and variables with a nonnormal distribution, even after
logarithmic transformation, were tested using the Mann–Whitney U test. Sex distribution
was tested using a chi-squared test. All data are presented as the mean ± standard error
(SE), and a two-tailed p-value < 0.05 was considered significant. Additionally, we compared
the predictive ability for T2DM between the conventional model and the new model with
the addition of the two biomarkers using the AUC calculated from logistic regression
analysis for each study.
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